Ginkgo Biloba - Treatment for Schizophrenia

Natural Schizophrenia Treatments

Why YOU Need SBX & Ginkgo Biloba:

Because at least six clinical trials (including those below) have shown Ginkgo Biloba to be effective in treating positive and negative symptoms of schizophrenia.

In particular, Ginkgo Biloba when taken with an antipsychotic, has been shown to be more effective in treating the positive symptoms of schizophrenia, than an antipsychotic alone.

Ginkgo Biloba is a natural plant extract, that has antioxidant properties, that has been used in Chinese Medicine for thousands of years and it has few, if any negative side effects.

SBX is a natural supplement designed to treat schizophrenia, it contains Ginkgo Biloba

In the Zhang study: Doctors (Zhang et al.), conducted a clinical trial involving 109 patients with chronic schizophrenia in China, in 2001. Patients were treated with either a). an antipsychotic and up to 360mg of extract of Ginkgo Biloba (EGb) or b). an antipsychotic and a placebo, per day. Zhang and his other colleagues indicated that in patients with chronic, refractory schizophrenia, extract of Ginkgo Biloba added to an antipsychotic was more effective than placebo added to antipsychotic in treating positive symptoms of schizophrenia.

In the Luo study:A clinical trial using 545 patients with schizophrenia in China was conducted in 1997. Patients were divided randomly into 2 groups. One group received 120mg of extract of Ginkgo Biloba three times daily and the other control group received a placebo. Patients in both groups received their maintenance neuroleptics throughout the 16-week research treatment. The patients' rating scores of brief psychiatric rating scale (BPRS) and Scale for the Assessment of Negative Symptoms showed a much greater reduction in the group receiving Ginkgo Biloba than those in the control group, from the sixth week of treatment. Extract of Ginkgo Biloba presented a better therapeutic effect for chronic patients with schizophrenia than the control when rated with traditional global rating method as well. On this rating 44.98% showed a marked improvement in the Ginkgo Biloba group compared to 20.98% in the control group. In conclusion, Dr Luo and other doctors found that combining Ginkgo Biloba extract and neuroleptics was an effective medicine for chronic patients with schizophrenia. Moreover, it appeared to have few side effects within the recommended dose range.

In the Atmaca study: A clinical trial took place in Turkey in 2005. Atmaca et al. suggested that the extract of Ginkgo Biloba may enhance the efficiency of the antipsychotic haloperidol in patients with chronic schizophrenia, especially on positive symptoms. The patients were randomly assigned to two groups: olanzapine plus Ginkgo Biloba (group I) and olanzapine (group II). At the evaluation of week 8, a significant difference in the mean Scale for the Assessment of Positive Symptoms (SAPS) scores but not in the Scale for the Assessment of Negative Symptoms scores between the groups was found.

In the Fanqiang study: A double-blind placebo controlled study took place in Bejing in 1996 with 36 patients. Patients were randomly divided into 2 groups and were given either Ginkgo Biloba or placebo for 8 weeks. It was concluded that within a specific dosage range Ginkgo Biloba is clinically effective for reducing the symptoms of schizophrenia.

In the Singh study: In 2010, a study took place in the United Kingdom to review the roles of antioxidants in the pathophysiology of schizophrenia, to confirm whether Ginkgo Biloba can reduce the symptoms of schizophrenia, and evaluate available literature to test this assumption. The six studies that fulfilled the selection criteria were constituted of 466 cases on Ginkgo Biloba and 362 cases on placebo. They all used the Scale for the Assessment of Negative Symptoms (SANS) to measure negative symptoms, and the Scale for the Assessment of Positive Symptoms (SAPS) or the Brief Psychiatric Rating Scale (BPRS) to measure total symptoms. Difference between the Ginkgo Biloba and control groups from their pre and post-trial scores and its pooled standard deviation were used to compute standardized mean difference (SMD). Ginkgo Biloba as an add-on therapy to antipsychotic medication produced statistically significant moderate improvement (SMD=-0.50) in total and negative symptoms of chronic schizophrenia. EGb as add-on therapy ameliorates the symptoms of chronic schizophrenia.

In the Doruk study: In 2008 a group of doctors conducted a placebo-controlled study in Turkey. They used 42 chronic, treatment-resistant patients with schizophrenia. The focus of this study was the systematic evaluation of the clinical effects of the extract of Ginkgo Biloba as an adjunct to the atypical antipsychotic (clozapine) in the treatment of refractory schizophrenia. The patients who were maintained on optimal doses of an antipsychotic, were administered either 120 mg/day of Ginkgo Biloba or placebo for 12 weeks. Clinical evaluations with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms were completed bi-weekly. The use of Ginkgo Biloba as an adjunct to clozapine was effective in decreasing negative symptoms in patients with treatment-resistant schizophrenia.

What is Ginkgo Biloba?

The extract of Ginkgo Biloba is taken from ginkgoes. Ginkgoes are one of the oldest living trees; the fossil record dates its existence as far back as the Mesozoic period (63 million to 230 million years ago). Considered a sacred tree throughout China, it has been used as a medicine for thousands of years.